NCT00807261Unknown2 期
PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 30
研究概览
简要总结
To determine the activity of weekly Docetaxel and Gemcitabine in patients with advanced soft tissue sarcoma previously treated with anthracycline and/or ifosfamide
- Primary endpoint: response rate
- Secondary endpoint: progress-free survival, overall survival, safety
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed recurrent or metastatic, unresectable soft tissue sarcoma or bone sarcoma with the exception of certain histopathologic subtypes of sarcomas recognized by experts to derive no benefit from conventional chemotherapy (e.g., alveolar soft part sarcoma, clear cell sarcoma, chondrosarcoma, chordoma, desmoid tumors)
- •Bone sarcoma patients must have visceral metastatic disease (e.g., metastatic to lung or liver)
- •Patients who were previously treated with anthracycline- and/or ifosfamide- containing chemotherapy, as a first-line chemotherapy for metastatic disease, or adjuvant therapy Patients may have had up to 2 prior chemotherapies within 4 weeks of starting the study treatment
- •unidimensional measurable lesions
- •Age ≥ 16 years
- •Life expectancy of more than 3 months
- •ECOG performance status ≤ 2
- •Adequate bone marrow function (ANC≥1,500/mm3, and platelet count ≥100,000/mm3)
- •Adequate kidney function (serum creatinine ≤ 1.5 mg/dL)
- •Adequate liver function (bilirubin ≤ 2 mg/dl and transaminase level ≤ 3 times the upper normal limit, or < 5 times for patients with liver metastasis, serum alkaline phosphatase < 2.5 times the upper normal limit, or < 5 times if liver metastases were present or < 10 times if bone metastases were present).
- •Adequate cardiac function (Ejection fraction ≥ 50% by echoCG or MUGA scan)
- •All patients are fully informed about the nature and purpose of this study and should give informed consent before the start of treatment.
排除标准
- •Pregnant or lactating patients
- •Patients with resectable lung metastasis
- •Presence or history of CNS metastasis
- •Prior history of other cancer within past 5 years, asides from basal cell and squamous cell carcinoma of skin, and carcinoma in situ of uterine cervix
- •Any preexisting medical condition of sufficient severity to prevent full compliance with the study.
研究者
相似试验
已完成
1 期
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaNCT01719302University of Vermont6
已完成
不适用
Gemcitabine and docetaxel in advanced soft tissue sarcomasadvanced soft tissue sarcomasJPRN-UMIN000007360agoya University Graduate School of Medicine50
已完成
2 期
Docetaxel in Treating Patients With Persistent or Recurrent Cervical CancerCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedRecurrent Cervical CarcinomaNCT00041093Gynecologic Oncology Group27
已完成
2 期
Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck CancerHead and Neck CancerNCT01645748Chonnam National University Hospital35
撤回
不适用
Platinum-Resistant, Recurrent Epithelial Ovarian CancerOvarian CancerNCT00484666Carilion Clinic